BID Equity Fund II, a fund advised by BID Equity, acquires a majority stake in XClinical GmbH. XClinical is a leading international provider of software solutions for drug and medical device studies. The XClinical platform fully implements the CDISC standard, which significantly accelerates the analysis and submission of data to regulatory authorities.
XClinical was founded in 2002 and offers its comprehensive SaaS platform “Marvin”, a tailor-made software solution for the support of clinical studies. In addition to data management, it also includes randomization, study equipment management, patient surveys, coding, and reporting. It covers the processes from study design to submission of results to audiences. XClinical is characterized by a high degree of flexibility and short response times, and optimally meets the requirements of its customers. Nearly 50 employees in Munich, Basel, Nantes, and New Jersey support the software and its customers all over the world.
The investment by BID Equity enables XClinical to accelerate its international expansion, expand its product portfolio, and further increase its level of professionalization. Together with the management team BID Equity will pursue a buy & build approach to open up new markets and to firmly anchor XClinical in the fast-growing clinical trials market. “With XClinical we are adding another fast-growing company to our portfolio, which we will support in its development with our many years of experience in optimizing software business models,” says the BID Equity team.
“We have selected BID Equity because we are absolutely convinced that we can jointly succeed in implementing our Buy & Build strategy in the area of eClinical Solutions Software”, Franciscus Pijpers, CEO of XClinical GmbH.